4.5 Review

Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches

Journal

MOLECULAR BIOLOGY REPORTS
Volume 48, Issue 9, Pages 6513-6524

Publisher

SPRINGER
DOI: 10.1007/s11033-021-06630-4

Keywords

COVID-19 genomics; Vaccine; Antiviral agents; Therapeutic approach

Ask authors/readers for more resources

Efforts are being made to develop efficient vaccines and treatments for SARS-CoV-2 infection, with therapeutic strategies focusing on inhibiting virus replication, enhancing immunity, and relieving COVID-19 symptoms. Multiple clinical trials are ongoing to assess the efficacy of antiviral substances, while vaccination campaigns using various vaccines are underway worldwide with efficacy rates between 72-95%. Further research and data are needed to confirm the safety of available vaccines.
We give a summary of SARS-genetic CoV-2's structure and evolution, as well as current attempts to develop efficient vaccine and treatment methods for SARS-CoV-2 infection, in this article. Most therapeutic strategies are based on repurposing of existing therapeutic agents used against various virus infections and focused mainly on inhibition of the virus replication cycle, enhancement of innate immunity, and alleviation of CRS caused by COVID-19. Currently, more than 100 clinical trials on COVID-19 aim to provide robust evidence on the efficacy of the currently available anti-SARS-CoV-2 antiviral substances, such as the nucleotide analogue remdesivir, the antimalarial drug chloroquine, and drugs directed against docking of SARS-CoV-2 to the membrane-associated angiotensin-converting enzyme 2 (ACE2) such as transmembrane protease serine 2 (TMPRSS2). The current vaccination campaign is ongoing worldwide using different types of vaccines such as Pfizer-BioNTech and Moderna, Johnson & Johnson, Oxford-AstraZeneca, Novavax, and others with efficacy ranging from 72-95%. In March 2021 Germany limited the use of the Oxford-AstraZeneca COVID-19 vaccine to people 60 years of age and older due to concerns that it may be causing blood clots. Further study and more data are needed to confirm the safety of different available vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available